The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

In particular, it is said to be fatal, with an average survival period of only 3 to 5 years after diagnosis. Although the domestic prevalence of idiopathic pulmonary fibrosis is known to be around ...

Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

In idiopathic pulmonary fibrosis, higher risk of mortality and lung transplant is linked to small decreases in FVC% predicted and DLCO% predicted.

with an average survival time of only three to five years from diagnosis. There are also several side effects with approved IPF drugs, including commonly reported symptoms such as diarrhoea ...

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition ... depriving the body of oxygen. The average survival time after diagnosis is typically 3-5 years, although this can vary widely.

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Leg-spinner Yuzvendra Chahal's maiden six-wicket for India as the hosts beat England by 75 runs in the third and final Twenty20 International ...

In IPF, the lungs become increasingly damaged by ... despite the availability of drug treatments. It has an average survival time of only three to five years from diagnosis. One of the top drugs ...

The two ant-fibrotic drugs currently approved for the treatment of IPF can slow the decline of lung function but are not curative, do not improve overall survival, and both come with significant ...

Rein previously announced positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF, in which a positive trend was observed in seven out of eight biomarkers ...